Array BioPharma Enterprise Value:
673.05M for May 17, 2013Array BioPharma Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 17, 2013 | 673.05M |
| May 16, 2013 | 649.69M |
| May 15, 2013 | 677.13M |
| May 14, 2013 | 669.54M |
| May 13, 2013 | 659.03M |
| May 10, 2013 | 620.50M |
| May 9, 2013 | 599.48M |
| May 8, 2013 | 583.13M |
| May 7, 2013 | 597.14M |
| May 6, 2013 | 662.54M |
| May 3, 2013 | 678.89M |
| May 2, 2013 | 668.38M |
| May 1, 2013 | 648.52M |
| April 30, 2013 | 680.05M |
| April 29, 2013 | 692.37M |
| April 26, 2013 | 683.03M |
| April 25, 2013 | 712.20M |
| April 24, 2013 | 709.87M |
| April 23, 2013 | 709.87M |
| April 22, 2013 | 680.70M |
| April 19, 2013 | 652.69M |
| April 18, 2013 | 625.85M |
| April 17, 2013 | 608.93M |
| April 16, 2013 | 595.52M |
| April 15, 2013 | 586.18M |
| April 12, 2013 | 624.69M |
| April 11, 2013 | 604.85M |
| April 10, 2013 | 594.93M |
| April 9, 2013 | 576.85M |
| April 8, 2013 | 568.68M |
| April 5, 2013 | 575.68M |
| April 4, 2013 | 579.18M |
| April 3, 2013 | 555.84M |
| April 2, 2013 | 558.18M |
| April 1, 2013 | 553.51M |
| March 28, 2013 | 558.04M |
| March 27, 2013 | 566.21M |
| March 26, 2013 | 560.38M |
| March 25, 2013 | 526.54M |
| March 22, 2013 | 485.71M |
| March 21, 2013 | 475.21M |
| March 20, 2013 | 465.88M |
| March 19, 2013 | 461.21M |
| March 18, 2013 | 460.05M |
| March 15, 2013 | 459.46M |
| March 14, 2013 | 464.71M |
| March 13, 2013 | 463.55M |
| March 12, 2013 | 488.05M |
| March 11, 2013 | 498.55M |
| March 8, 2013 | 504.38M |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
ARRY Enterprise Value Benchmarks
| Companies | |
|---|---|
| Ariad Pharmaceuticals | 2.666B |
| Insmed | 275.02M |
| Celldex Therapeutics | 853.92M |
ARRY Enterprise Value Rankings
| Overall |
68th percentile 2356 of 7593 |
| Sector |
67th percentile 209 of 650 in Healthcare |
| Industry |
79th percentile 48 of 237 in Biotechnology |
ARRY Enterprise Value Range, Past 5 Years
| Minimum | 116.95M | Mar 9 2009 |
| Maximum | 712.20M | Apr 25 2013 |
| Average | 250.00M |
